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SUMMARY
Cytomegalovirus (CMV) infection is the most common congenital infection, affecting 0.4% to 2.3%  newborns. Most of them are
asymptomatic at birth, but later 10% develop handicaps, mainly neurological disturbances. Our aim was to determine the prevalence
of CMV shed in urine of newborns from a neonatal intensive care unit using the polymerase chain reaction (PCR) and correlate
positive cases to some perinatal aspects. Urine samples obtained at first week of life were processed according to a PCR protocol.
Perinatal data were collected retrospectively from medical records. Twenty of the 292 cases (6.8%) were CMV-DNA positive. There
was no statistical difference between newborns with and without CMV congenital infection concerning birth weight (p=0.11), gestational
age (p=0.11), Apgar scores in the first and fifth minutes of life (p=0.99 and 0.16), mother’s age (p=0.67) and gestational history.
Moreover, CMV congenital infection was neither related to gender (p=0.55) nor to low weight (<2,500g) at birth (p=0.13). This high
prevalence of CMV congenital infection (6.8%) could be due to the high sensitivity of PCR technique, the low socioeconomic level
of studied population or the severe clinical status of these newborns.
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INTRODUCTION
Cytomegalovirus (CMV), a ubiquitous microrganism, is responsible
for the most common and widespread congenital infection all over the
world, affecting 0.4% to 2.3% of all newborns5,20. In selected populations
such as those infants from neonatal intensive care units (NICU), figures
are even larger13. Transplacental transmission of CMV may occur either
due to maternal primary infection (especially in low prevalence
populations) or to recurrent infections (reactivation or reinfection) during
pregnancy9,21. Previous studies8,12,19,21,23 have pointed out that age, race,
sexual activity, marital status, parity, socioeconomic background and
contact with potential sources of CMV (eg. children in day care centers)
are risk factors for delivering a congenitally infected newborn.
Fortunately, most of the infected children do not present signs of the
disease at birth or soon thereafter, but up to 10% may have a severe
symptomatic course or even long-term sequelae ranging from discrete
learning disabilities to frank hearing loss or other ocular and neurological
handicaps1,5,15,20,21. The importance of promptly diagnosing CMV
infection resides in both the perspectives of intervening therapeutically
to minimize morbidity, mortality and sequelae and of determining risk
factors for future abnormalities5,20.
Classically, the gold standard diagnostic technique for congenital
CMV infection has been viral isolation in urine, although usually only
serology is available in daily practice, with its obvious limitations3,10.
Alternative approaches have emerged, of which the polymerase chain
reaction (PCR) is especially promising for its high sensitivity, specificity
and relative simplicity2,3,6,7,24,25.
In Brazil, studies have shown that prevalence of IgG antibodies to
CMV in pregnant women range from 66.5% to 92% depending on the
applied technique (enzyme linked immune assay or complement-fixing
reaction, usually higher in the later)11 and on the social background of
the studied population (low or middle socioeconomical level, higher in
the former)14,22. Concerning congenital CMV infection assessed by viral
isolation, its prevalence rates have been found to range from 0.46% and
0.92% in low and middle socioeconomical level populations
respectively14. Recently, there has also been a report on the use of the
PCR versus viral isolation in congenital and perinatal CMV infection25,
but prevalence studies in neonatal intensive care units applying this
technique are still lacking in Brazil.
Our study aimed at using this novel technique so as to determine the
prevalence of congenital CMV infection in a selected population of
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infants in a NICU unit from a university hospital and to relate it to some
perinatal findings.
PATIENTS AND METHODS
From 1995 to 1998, we studied 292 newborns from Hospital das
Clínicas da Universidade Federal de Minas Gerais (HC-UFMG) selected
at random, all of them from the NICU. Urine sample from each newborn
was collected in the first week of life and stored in a freezer until
processed.
PCR was performed using two pairs of primers that anneal to well-
conserved immediate early (IE) and late (LA) transcripted regions of
CMV genome leading to amplification of 393 and 139 bp fragments,
respectively (Table 1).
From two milliliters of urine collected, 1mL was used for stock and
1mL for DNA extraction. The latter consisted of centrifugation at 5,000
rpm for 15 minutes followed by discharge of the supernatant and
suspension of the pellet (urine sediment) in 200µL of PCR buffer (2.5mL
KCl 2M, 1mL Tris-HCl 1M pH 8, 250µL MgCl2 1M, 10mg gelatin,
450µL NP40, 450µL Tween 20 and H2O q.s.p. 100 mL). Six microliters
of proteinase K solution (20mg/mL) were then added and incubated at
52 ºC for two hours. Finally, the enzyme was inactivated by boiling at
100 ºC for seven minutes. Reaction mixture consisted of 3µL of the
former DNA suspension, 2.5µL of 10X PCR buffer (15mM MgCl2, 500
mM KCl, 100 mM Tris-HCl pH=8), 6 pmol of each of the four
deoxynucleotide triphosphates, 0.75 IU of Taq DNA polymerase, 20
pmol of each primer and deionized water to get a final volume of 25µL.
DNA amplification was performed in a MJ Research MiniCyclerTM (initial
five-minute-denaturation at 94 ºC, two-minute-annealing and extension
at 72 ºC followed by 34 cycles of thirty-second-denaturation at 94 ºC
and two-minute-annealing and extension at 72 ºC, at the end of the
programme, a seven-minute-final-extension at 72 ºC). All amplification
reactions contained a positive (one microliter of extracted CMV DNA
from positive urine) and negative (3µL of deionized water) controls.
Products were submitted to electrophoresis and analyzed in silver-stained
6% polyacrilamide gels16.
Congenital CMV infection was defined as amplification of CMV
DNA by either or both IE and LA primers in urine collected in the first
week of life. All positive cases were confirmed in a second test.
Data on the newborns and their mothers were collected
retrospectively from livebirth declaration forms (“Declaração de Nascidos
Vivos” – DNV), “Centro Latinoamericano de Perinatalogia” (CLAP-
OPS/OMS) perinatal clinical history forms and medical records.
Unfortunately, not all data were accessible for all patients due to
incomplete and/or inadequate filling of the available records. Variables
were considered suitable for statistical analysis when they were missing
in less than 5% of the patients.
Statistical analysis were performed in Epi Info Software4 using Chi-
square or Fisher (comparison of frequencies), ANOVA (comparison of
means) and Kruskal-Wallis (comparison of medians) tests, depending
on the data profile and distribution. P value was considered statistically
significant when <0.05.
RESULTS
During the study interval, 292 newborns had urine samples analyzed:
179 males (61.3%) and 113 females (38.7%). Mean gestational age,
weight, stature and cephalic perimeter at birth were respectively 35.3±2.8
weeks (median: 35 weeks), 2,226±751g (median: 2,100g), 44.4±4.1cm
(median: 44.5cm) and 32.1±3.5cm (median: 32cm). Apgar scores at one
and five minutes showed respective mean values of 6.5±2.5  (median: 8)
and 8.4±1.2 (median: 9). Mean hospital stay  was 22.0±23.8 days
(median: 14 days). Mothers had a mean age of 26.9±6.9 years (median:
26 years), most of them were married or had a stable union (73.2%) and
had only elementary education (72.4%). Their gestational history showed
a mean of 1.4 deliveries (median: 1 delivery) and 0.3 miscarriage (median:
no miscarriage).
Among the 292 newborns, 20 (6.8%) showed CMV-DNA in urine
during their first week of life, indicating congenital infection (Table 2).
In ten newborns, only LA primers yielded DNA amplification; in seven
both LA and IE did so and in the remaining three newborns, only target
DNA for IE primers was amplified.
Data loss did not differ when analyzing the frequency of CMV-DNA
positive and negative subjects among those whose variables where
available and those whose variables were missing.
Variables with less than 5% loss were analyzed (Table 2). Comparing
non-infected versus CMV infected newborns, mean weight did not differ
(2,245±748g versus 1,967±763g; p=0.11), so as gestational age medians
(35 weeks versus 35 weeks; p=0.11).  One and five-minute-Apgar scores
showed similar medians in the two groups (p=0.99 and p=0.16) (Table
2). Low birth weight (<2500g) and normal birth weight (≥2500g) were
not statistically related to CMV congenital infection (p=0.13). There
were also no gender differences concerning CMV infection (p=0.55)
(Table 2).
Table 1
Primers used in the polymerase chain reaction
        Primer Sequence Product size Target region
LA1 (upstream) 5’ CCG CAA CCT GGT GCC CAT GG  3’ 139bp gp64 late antigen †
LA2 (downstream) 5’ CGT TTG GGT TGC GCA GCG GG  3’
IE1  (upstream) 5’ GCT GCG GCA TAG AAT CAA GGA GCA C 3’ 393bp immediate early ‡
IE2  (downstream) 5’ GGT TGG TGG TCT TAG GGA AGG CTG AG 3’ gene
†: SHIBATA et al, 1988; ‡: BORG et al., 1995
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Mother’s age was slightly higher in CMV infected  newborns (medians:
28.5 versus 26 years), although not statistically significant (p=0.67). A
similar situation was observed when comparing both groups concerning
parity (p=0.25) and number of miscarriages (p=0.51) (Table 2).
DISCUSSION
In Brazil, studies applying polymerase chain reaction in the diagnosis
of CMV congenital infection are still scarce25, especially those dealing
with prevalence in a significant number of newborns and specifically in
a neonatal intensive care unit. In this regard, we are adding important
data to the knowledge of this subject. Moreover, we tried to correlate
CMV congenital infection with some features linked to the infants and
their mothers. In this analysis, it is essential to bear in mind that since
previous maternal serological status was not available, we could be
assessing not only factors influencing transplacental infection but also
maternal infection12.
Despite the high prevalence of congenital CMV infection in our
investigation (6.8%), values up to 10% have been described when
studying infants from NICU elsewhere using the PCR13. The low
socioeconomical level of the studied population and, mainly, the clinical
status of the newborns (from a NICU) possibly influenced the high
prevalence rate of congenital CMV infection now described as compared
with that of the general population.
It is established that in populations with unfavourable socioeconomical
conditions congenital CMV infection is more prevalent14,21. Besides, the
expected number of infected newborns among those in worse clinical
conditions is higher than in the general population, once the deleterious
effects determined by the virus begin in the fetus. Finally the high sensitivity
of the applied technique may have contributed towards a higher detection
of congenital infection13,25. However, if from one side PCR improves
sensitivity, from the other one must be aware of the risk of false positive
results, essentially through contamination. So we tried to attenuate this
risk performing DNA extraction, amplification and electophoresis phases
in separated rooms, using positive and negative controls and making a
second corfirmatory PCR test in all positive cases in the first reaction.
It is known that some variables are related to a higher or lower risk
of delivering a CMV congenitally infected newborn8,12,19,21,23. In this
studied population, we could not detect any difference between the group
with and without congenital CMV infection concerning the analyzed
maternal data (Table 2). Congenital CMV infection is a established cause
of intrauterine growth restriction (IUGR). However, in our sample, birth
weight was not different between infected and non-infected newborns
(1,967±763g versus 2,245±748g; p=0.11). This finding may possibly
be related to the profile of the newborns, since most of them, coming
from the NICU, were affected by fetal or maternal diseases that cause
IUGR. An analogous interpretation can be made concerning gestational
age in these patients (medians: 35 versus 35 weeks; p=0.11), once there
were other prevalent causes of prematurity in this population. Apgar
scores did also not differ between the two groups, as other maternal
aspects like age and gestational history.
Infected infants are being followed periodically by the infectologist
staff of HC-UFMG. In the first visit, CMV serology, a skull x-ray and/
or a transfontanel ultrasound and a fundoscopic examination are
performed. The infant is then followed clinically in intervals of three
months until two years old, when an audiometry test is performed. After
that, the child is examined anually so as to evaluate his/her development.
In our experience, PCR technique showed to be useful and effective
in the early diagnosis of congenital CMV infection.
Table 2
Comparison between newborns with and without congenital cytomegalovirus infection from a university hospital neonatal intensive care unit
Mean/median/frequency
Variable CMV(+)group CMV(-)group Missing data p-value
 (n=20) (n=272)
Newborn
Birth weight (g, mean ± SD) 1,967 ± 763 2,245 ± 748 0% 0.11†
Low      (<2500g) 17 (85%) 188 (69.1%) 0% 0.13φ
Normal (≥2500g) 3 (15%) 84 (30.9%)
Gender 0% 0.55φ
Male 11 (55%) 168 (61.8%)
Female 9 (45%) 104 (38.2%)
Gestational age (weeks, median) 35 35 1.7% 0.11‡
Apgar score at 1’ (median) 8 8 2.1% 0.99‡
Apgar score at 5’ (median) 9 9 1% 0.16‡
Mother
Mother’s age (years, median) 28.5 26 0.7% 0.67‡
No. of deliveries (median) 1 1 3.8% 0.25‡
No. of miscarriages (median) 0 0 3.8% 0.51‡
SD: standard deviation; †: ANOVA between CMV(+) and CMV(-) groups; φ: Chi-square test between CMV(+) and CMV(-) groups; ‡: Kruskal-Wallis H test
between CMV(+) and CMV(-) groups
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RESUMO
Infecção congênita pelo citomegalovírus em unidade neonatal de
alto risco de um hospital universitário no Brasil: prevalência
avaliada pela PCR e associação com alguns aspectos perinatais
A citomegalovirose é das infecções congênitas mais prevalentes,
acometendo de 0,4% a 2,3% dos nascidos vivos. A maioria dos recém-
nascidos (RN) infectados é assintomática, mas até 10% desenvolvem
seqüelas variadas, principalmente neurossensoriais. Objetivamos
determinar a prevalência do CMV na urina de RN através da PCR,
correlacionando-a a alguns achados perinatais. Analisamos amostras de
urina colhidas na 1ª semana de vida de 292 RN do HC-UFMG, todos
internados na unidade neonatal de alto risco. DNA viral foi amplificado
segundo protocolo de PCR. Os dados perinatais foram colhidos
retrospectivamente de registros médicos. Na população estudada, 20 dos
292 casos (6,8%) mostraram positividade para o DNA-CMV. Não houve
diferença estatisticamente significante entre os RN com e os sem infecção
congênita pelo CMV quanto a peso ao nascer (p=0,11), idade gestacional
(p=0,11), índice de Apgar no 1º e 5º minutos (p=0,99 e 0,16), idade da
mãe (p=0,67) e história gestacional materna. Também não se observou
associação da infecção congênita pelo CMV com baixo peso ao nascer
(p=0,13) ou sexo do RN (p=0,55). A alta prevalência da infecção
congênita neste estudo (6,8%) pode ser devida  à elevada sensibilidade
da PCR, ao baixo nível sócio-econômico da população estudada ou às
características clínicas mais graves desses RN.
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